Mylan and Lupin have gained the necessary recommendation to begin marketing their etanercept biosimilar in Europe.
Nepexto, an etanercept biosimilar, has gained a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending use of the product.
Nepexto has received a positive opinion for all indications of the reference product (Enbrel), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and nonradiographic axial spondyloarthritis), plaque psoriasis, and pediatric plaque psoriasis, according to Mylan NV and Lupin Limited, which have partnered in the development of the biosimilar.
“This milestone brings us 1 step closer to bringing an affordable biosimilar to etanercept to the European market through our partner Mylan,” said Vinita Gupta, chief executive officer of Lupin, in a statement. The companies began collaborating in 2018 to bring an etanercept biosimilar to the European market.
Enbrel, marketed by Amgen and Wyeth Pharmaceuticals, had sales of roughly $9.6 billion globally in 2019, according to IQVIA. In the United S, the comparable revenue figure was $5 billion.
The EMU committee opinion was based on a bioequivalence assessment that included preclinical and clinical studies. In addition, a phase 3 clinical study in patients with moderate-to-severe active rheumatoid arthritis confirmed equivalence of Nepexto to the reference product in terms of efficacy, safety, and immunogenicity, the statement said.
There are 2 approved etanercept biosimilars in the US: Samsung Bioepis’ Eticovo and Sandoz’ Erelzi. However, neither has launched. Erelzi received FDA approval in 2016 and has been delayed by litigation. Eticovo was approved in 2019, and no launch date has been announced.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.